The target antigen determines the mechanism of acquired resistance to T cell-based therapies.
5-AZA
CEA
CP: Cancer
HER2
T cell bispecific antibody
antigen
immunotherapy
interferon-gamma patient-derived xenografts
resistance
Journal
Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691
Informations de publication
Date de publication:
18 10 2022
18 10 2022
Historique:
received:
02
11
2021
revised:
20
06
2022
accepted:
08
09
2022
entrez:
19
10
2022
pubmed:
20
10
2022
medline:
22
10
2022
Statut:
ppublish
Résumé
Despite the revolution of immunotherapy in cancer treatment, patients eventually progress due to the emergence of resistance. In this scenario, the selection of the tumor antigen can be decisive in the success of the clinical response. T cell bispecific antibodies (TCBs) are engineered molecules that include binding sites to the T cell receptor and to a tumor antigen. Using gastric CEA
Identifiants
pubmed: 36261015
pii: S2211-1247(22)01271-2
doi: 10.1016/j.celrep.2022.111430
pii:
doi:
Substances chimiques
Antibodies, Bispecific
0
Carcinoembryonic Antigen
0
Interferon-gamma
82115-62-6
Receptors, Antigen, T-Cell
0
Banques de données
ClinicalTrials.gov
['NCT02650713', 'NCT02324257']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111430Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests M.B. declares employment, stock ownership, and patents with Roche. C.K. declares employment, stock ownership, and patents with Roche. J.A. has received research funds from Roche, Synthon, Menarini, and Molecular Partners, and consultancy honoraria from Menarini.